This study aims to see if a new treatment called V940, combined with another medicine called pembrolizumab, helps prevent melanoma (a type of skin cancer) from coming back. V940 is a special therapy that uses something called _neoantigens_, which are parts of cancer cells that help the body’s immune system recognize and fight the cancer. Pembrolizumab, also known as MK-3475, is a drug that helps the immune system attack cancer cells. Researchers want to compare whether V940 plus pembrolizumab works better than pembrolizumab alone.

To join this study, you must have had surgery to remove certain types of melanoma (Stages IIB, IIC, III, or IV) and be free of cancer now. You should not have had any other cancer treatments except surgery. There are some health conditions that might prevent you from joining, like having cancer that has spread too much or a history of severe reactions to medications.

• Study Length: The length of the study and number of visits are not provided.
• Compensation: There is no mention of compensation in the study details.
• Risks: Possible risks include reactions to study medications.